Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Active Treatment- CT1812 100 mg
DRUG: Active Treatment- CT1812 300 mg
DRUG: Placebo

Sponsor

Cognition Therapeutics

Collaborators

[object Object]